Effectiveness of local ablation therapy for the treatment of Intermediate stage hepatocellular carcinoma

Effectiveness of local ablation therapy for the treatment of Intermediate stage hepatocellular carcinoma - Local ablation therapy for Intermediate stage hepatocellular carcinoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046507

Enrollment

Registered

2022-01-01

Start date

2022-04-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Child Pugh A or B 2. Tumor number over 3 and up-to-7 in 3. All tumor nodules were planned to treat by local ablation therapy or transcatheter arterial chemoembolization 4. Treatment naive tumor or curatively treated over 6 months ago (include only first recurrence).

Exclusion criteria

Exclusion criteria: 1. Tumor with vascular invasion or distant metastasis 2. Tumors were exceeded 3cm or 3 nodules, or vascular invasion or distant metastasis was presented at prior treatment. 3. Multiple primary cancer 4. Patients who were considered to be inappropriate for the study.

Design outcomes

Primary

Measure	Time frame
Recurrence free survival	—

Secondary

Measure	Time frame
Local and distant recurrence rates Treatment success rate Changes of liver function Adverse events Length of admission and cost-effectiveness Time to up-to-7 out Time to treatment failure Overall survival	—

Countries

Japan

Contacts

Public ContactHideki Onishi

Okayama University Hospital Department of Gastroenterology and Hepatology

hdk0024@gmail.com086-235-7219

Outcome results